

## Special Issue

# The Aging Metabolism: Diabetes, Obesity, and Lifespan Insights

### Message from the Guest Editors

Metabolic diseases, including diabetes and obesity, represent a growing global health challenge, particularly as populations age due to lower birth rates and increased life expectancy in Western society.

Understanding the molecular mechanisms, genetic and epigenetic factors, and pathophysiology underlying these disorders is essential in developing innovative interventions to promote healthy aging. This Special Issue will present cutting-edge research on metabolic and age-related diseases, focusing on diabetes and obesity and their interplay with the aging process. To align with the journal's scope, contributions may include studies on pathogenesis and disease mechanisms, molecular and cell signaling pathways, biomarkers for early diagnosis, pharmacological therapies, redox-related mechanisms, biopharmaceutical approaches, or microbiome interventions. This Special Issue will bring together high-quality preclinical and clinical results to advance our understanding of metabolic disorders and aging, with the aim of ultimately informing new therapies or precision medicine strategies to improve the healthspan and patient outcomes.

---

### Guest Editors

Dr. Rafael Ramírez-Carracedo

Department of Surgery, Medical and Social Sciences, Area of Human Anatomy and Embryology, School of Medicine and Health Sciences, Universidad de Alcalá, Madrid, Spain

Dr. Rafael Moreno-Gómez-Toledano

Department of Surgery, Medical and Social Sciences, Area of Human Anatomy and Embryology, School of Medicine and Health Sciences, Universidad de Alcalá, Madrid, Spain

---

### Deadline for manuscript submissions

30 June 2026



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/258359](https://mdpi.com/si/258359)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).